About Segue Therapeutics
Segue Therapeutics is a Healthcare company based in New Orleans (United States) founded in 2016. It operates as a proprietary high content imaging platform to discover and commercialize repurposed drugs for the treatment of cancer, fibrosis and fungal infections. Segue Therapeutics has raised $170 thousand across 2 funding rounds from investors including HHS. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and Revolution Medicines and 2 more; 6 of its 7 listed competitors have raised funding.
Company details
Segue Therapeutics was founded in 2016 in New Orleans, United States, as an early-stage biotechnology firm. A proprietary high-content imaging platform is employed to identify and advance repurposed drugs targeting cancer, fibrosis, and fungal infections. The pipeline features ST1001, a cardiac glycoside in preclinical stages for pancreatic cancer and fibrosis, alongside an FDA-approved migraine treatment under development for cancer applications.
- Headquarters New Orleans, United States
- SectorsHealthcare
- Website seguetx.com
- Total Equity Funding$170K (USD)
in 2 rounds
- Latest Funding Round$274.63K (USD), Grant
Sep 2019
- Investors
Funding Insights of Segue Therapeutics
Segue Therapeutics has successfully raised a total of $170K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $274.63 thousand completed in September 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $170,000
- Total Rounds 2
- Last Round Grant — $274,631
- First Round $170,000
(Jul 2016)
- Investors Count 1
All 2 funding rounds of Segue Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2019 | $274,631 | Grant | – | – | |
| Jul 2016 | $170,000 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Segue Therapeutics
Segue Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Segue Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Segue Therapeutics
3 dated milestones of Segue Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Segue Therapeutics is founded.
- Funding First funding round of $170K.
- Funding Latest funding round, Grant, of $275K.
Competitors of Segue Therapeutics
Segue Therapeutics has 7 listed competitors in our database, 6 of them funded. They include Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and Revolution Medicines, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. |
Detailed competitors of Segue Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
10 companies that operate in the same segment as Segue Therapeutics (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Segue Therapeutics
Segue Therapeutics was founded in 2016.
Segue Therapeutics is headquartered in New Orleans, United States. It is registered at New Orleans, Louisiana, United States.
Segue Therapeutics is a funded company, having raised a total of $170K across 2 funding rounds to date. The company's 1st funding round was a Seed of $170K, raised on Jul 2016.
Segue Therapeutics was founded in 2016 in New Orleans, United States, as an early-stage biotechnology firm. A proprietary high-content imaging platform is employed to identify and advance repurposed drugs targeting cancer, fibrosis, and fungal infections. The pipeline features ST1001, a cardiac glycoside in preclinical stages for pancreatic cancer and fibrosis, alongside an FDA-approved migraine treatment under development for cancer applications.
Segue Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Segue Therapeutics has 1 investor. Key investors include HHS.